Putting Focus on Data From the 2018 Breast Cancer Meeting - prIME Oncology
prIME Clinical Update
prIME Clinical Update

Putting Focus on Data From the 2018 Breast Cancer Meeting

Practice-Changing Results Across the Disease Continuum

Not a member of My prIME? Join now for instant access.

Get insight from experts in breast cancer treatment on the most important data from the 2018 San Antonio Breast Cancer Symposium. This activity contains insights into how these data will be incorporated into routine practice.

Interactive Presentation

Interactive Presentation

CME

CME

0.5 AMA PRA Category 1 Credit™

Release Date

Release Date

Mar 15, 2019

Expiration Date

Mar 15, 2020

HER2+ Breast Cancer

Featured Experts

  • Eleni Andreopoulou, MD, Weill Cornell Medicine, New York City, New York, United States
  • Francisco Esteva, MD, PhD, FACP, New York University Langone Medical Center, New York, New York

Featured Topics

Abstract GS1-10: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE

Abstract P2-13-01: Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer: Subgroup analyses from the phase III ExteNET trial

Abstract PD3-06: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT trial

Abstract P6-17-22: Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167)

Abstract PD3-03: SOLTI-1303 PATRICIA phase II trial (STAGE 1) — Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer

Triple-negative Breast Cancer

Featured Experts

  • Eleni Andreopoulou, MD, Weill Cornell Medicine, New York City, New York, United States
  • Francisco Esteva, MD, PhD, FACP, New York University Langone Medical Center, New York, New York

Featured Topics

Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer

Abstract P2-09-03: Updated efficacy of first or second-line pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC) and correlations with baseline lymphocyte and naïve CD4+ T-cell count

Abstract PD5-02: Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple-negative breast cancer beyond BRCA: (TOPACIO/Keynote-162)

Abstract PD5-01: KEYNOTE-173: Phase 1b multicohort study of pembrolizumab (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative breast cancer (TNBC)

Abstract P3-10-09: Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro)+chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial

Abstract PD2-07: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial

  • Eleni Andreopoulou, MDWeill Cornell Medicine
    New York City, New York, United States
  • Francisco Esteva, MD, PhD, FACPNew York University Langone Medical Center
    New York, New York

This educational activity is specifically designed to meet the needs of practicing oncologists, oncology nurses, researchers, and other health care professionals involved and/or interested in the therapeutic management of patients with breast cancer and the consequences of this disease.

After successful completion of this educational activity, participants should be able to:

  • Describe important clinical findings in breast cancer management from the conference
  • Incorporate recent practice-changing breast cancer clinical data into routine practice

This educational activity is supported by a grant from Merck and Co., Inc.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Provider

This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete: 30 minutes

To contact Postgraduate Institute for Medicine please visit www.pimed.com.

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Andreopoulou has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Esteva has disclosed that he has received consulting fees from Celltrion, Genentech, Novartis Oncology, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Postgraduate Institute for Medicine planners and managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed no relevant financial relationships.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.